Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s Why

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $35.24, but opened at $33.45. Nanobiotix shares last traded at $32.6720, with a volume of 24,122 shares changing hands.

Analyst Ratings Changes

A number of brokerages have weighed in on NBTX. Guggenheim started coverage on shares of Nanobiotix in a research report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, Leerink Partners raised their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Trading Down 8.3%

The firm’s 50-day moving average is $38.90 and its 200 day moving average is $37.40.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.